209 related articles for article (PubMed ID: 35705430)
1. Relation of Body Mass Index to Transthyretin Cardiac Amyloidosis Particularly in Black and Hispanic Patients (from the SCAN-MP Study).
Poterucha TJ; Kurian D; Raiszadeh F; Teruya S; Elias P; Kogan R; Chiuzan C; Einstein AJ; Ruberg FL; Maurer MS
Am J Cardiol; 2022 Aug; 177():116-120. PubMed ID: 35705430
[TBL] [Abstract][Full Text] [Related]
2. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
[TBL] [Abstract][Full Text] [Related]
3. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
[TBL] [Abstract][Full Text] [Related]
4. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
5. Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis.
Batra J; Rosenblum H; Cappelli F; Zampieri M; Olivotto I; Griffin JM; Saith SE; Teruya S; De Los Santos J; Argiro A; Burkhoff D; Perfetto F; Maurer MS
J Card Fail; 2022 Jun; 28(6):950-959. PubMed ID: 34974181
[TBL] [Abstract][Full Text] [Related]
6. Sex Differences in the Phenotype of Transthyretin Cardiac Amyloidosis Due to Val122Ile Mutation: Insights from Noninvasive Pressure-Volume Analysis.
Batra J; Rosenblum H; Defilippis EM; Griffin JM; Saith SE; Gamino D; Teruya S; Santos JL; Helmke S; Burkhoff D; Maurer MS
J Card Fail; 2021 Jan; 27(1):67-74. PubMed ID: 32829019
[TBL] [Abstract][Full Text] [Related]
7. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
Lau ATC; DiDomenico RJ; Kim K
Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
[TBL] [Abstract][Full Text] [Related]
9. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
[TBL] [Abstract][Full Text] [Related]
10. A case of cardiac amyloidosis in an elderly Japanese patient with amyloidogenic transthyretin Val122Ile variant.
Ono R; Takahashi H; Sato T; Yamazaki T; Hori Y; Fukushima K
J Cardiol Cases; 2020 Nov; 22(5):221-225. PubMed ID: 33133314
[TBL] [Abstract][Full Text] [Related]
11. Association of Transthyretin Val122Ile Variant With Incident Heart Failure Among Black Individuals.
Parcha V; Malla G; Irvin MR; Armstrong ND; Judd SE; Lange LA; Maurer MS; Levitan EB; Goyal P; Arora G; Arora P
JAMA; 2022 Apr; 327(14):1368-1378. PubMed ID: 35377943
[TBL] [Abstract][Full Text] [Related]
12. Counseling Family Members and Monitoring for Evidence of Disease in Asymptomatic Carriers of Amyloid Transthyretin Cardiac Amyloidosis.
Barker N; Judge DP
Am J Cardiol; 2022 Dec; 185 Suppl 1():S43-S50. PubMed ID: 36216601
[TBL] [Abstract][Full Text] [Related]
13. The genetics of cardiac amyloidosis.
Arno S; Cowger J
Heart Fail Rev; 2022 Sep; 27(5):1485-1492. PubMed ID: 34518987
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo.
Arana-Achaga X; Goena-Vives C; Villanueva-Benito I; Solla-Ruiz I; Rengel Jimenez A; Gaspar TI; Urreta-Barallobre I; Barge-Caballero G; Seijas-Marcos S; Cabrera E; Garcia-Pavía P; Basurte Elorz MT; Ayestarán NM; Sierra LT; Robledo Iñarritu M; Lozano-Bahamonde A; Escolar-Perez V; Gómez-Ramírez C; Alzola E; Andrés RN; Francisco Matias JL; Limeres Freire J; Armengou Arxe A; Negre Busó M; Piqueras-Flores J; Martínez-Del Río J; Onaindia Gandarias JJ; Rodriguez Sanchez I; Querejeta Iraola R
JACC Cardiovasc Imaging; 2023 Dec; 16(12):1567-1580. PubMed ID: 37389511
[TBL] [Abstract][Full Text] [Related]
15. Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis.
Itzhaki Ben Zadok O; Vaturi M; Vaxman I; Iakobishvili Z; Rhurman-Shahar N; Kornowski R; Hamdan A
PLoS One; 2021; 16(8):e0255487. PubMed ID: 34370783
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
[TBL] [Abstract][Full Text] [Related]
17. Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.
Castano A; Haq M; Narotsky DL; Goldsmith J; Weinberg RL; Morgenstern R; Pozniakoff T; Ruberg FL; Miller EJ; Berk JL; Dispenzieri A; Grogan M; Johnson G; Bokhari S; Maurer MS
JAMA Cardiol; 2016 Nov; 1(8):880-889. PubMed ID: 27557400
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of Tc
Pandey S; Teruya S; Rodriguez C; Deluca A; Kinkhabwala M; Johnson LL; Fine D; Sabogal N; Winburn M; Castillo M; Bhatia K; Malkovskaya R; Raiszadeh F; Kurian D; Miller EJ; Einstein AJ; Maurer MS; Ruberg FL
J Nucl Cardiol; 2023 Aug; 30(4):1414-1419. PubMed ID: 36823486
[TBL] [Abstract][Full Text] [Related]
19. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Antonopoulos AS; Panagiotopoulos I; Kouroutzoglou A; Koutsis G; Toskas P; Lazaros G; Toutouzas K; Tousoulis D; Tsioufis K; Vlachopoulos C
Eur J Heart Fail; 2022 Sep; 24(9):1677-1696. PubMed ID: 35730461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
